[HTML][HTML] Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
R Qin, T Jin, F Xu - Frontiers in Immunology, 2023 - frontiersin.org
In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative
approach in treating advanced hepatocellular carcinoma (HCC). Despite their success …
approach in treating advanced hepatocellular carcinoma (HCC). Despite their success …
[HTML][HTML] Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response
Y Shakiba, PO Vorobyev, GM Yusubalieva… - Molecular Therapy …, 2023 - cell.com
We developed recombinant variants of oncolytic vaccinia virus LIVP strain expressing
interleukin-15 (IL-15) or its receptor subunit alpha (IL-15Rα) to stimulate IL-15-dependent …
interleukin-15 (IL-15) or its receptor subunit alpha (IL-15Rα) to stimulate IL-15-dependent …
[HTML][HTML] Preoperative splenic area as a prognostic biomarker of early-stage non-small cell lung cancer
M Liu, G Yan, Y Li, R You, L Liu, D Zhang, G Yang… - Cancer Imaging, 2023 - Springer
Background The correlation between the preoperative splenic area measured on CT scans
and the overall survival (OS) of early-stage non-small cell lung cancer (NSCLC) patients …
and the overall survival (OS) of early-stage non-small cell lung cancer (NSCLC) patients …
[HTML][HTML] Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint …
L Xiao, R Li, H Cui, C Hong, C Huang, Q Li, C Hu… - BMC cancer, 2022 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) have been used to successfully
treat primary liver cancer (PLC); however, identifying modifiable patient factors associated …
treat primary liver cancer (PLC); however, identifying modifiable patient factors associated …
Predictive value of the hepatic immune predictive index for patients with primary liver cancer treated with immune checkpoint inhibitors
C Hong, HZ Dong, RN Li, HB Zhu, QM Li, H Cui… - Digestive …, 2023 - karger.com
Abstract Background: Immune checkpoint inhibitors (ICIs) have improved survival outcomes
and resulted in long-term responses in primary liver cancer in some patients. Nevertheless …
and resulted in long-term responses in primary liver cancer in some patients. Nevertheless …
The augmentation of cytotoxic immune cell functionality through physical exertion bolsters the potency of chemotherapy in models of mammary carcinoma
B Qin, Z He, L Xie, S Feng, J Ye, J Gui, X Sun… - Cancer …, 2024 - Wiley Online Library
Background Mammary carcinoma, a pervasive and potentially lethal affliction, is conjectured
to be profoundly influenced by physical exercise, both in prophylaxis and therapeutic …
to be profoundly influenced by physical exercise, both in prophylaxis and therapeutic …
Possible pathogenic mechanisms for doxorubicin‐induced splenic atrophy in a human breast cancer xenograft mouse model
J Xue, B Ye, M Sun - Journal of Applied Toxicology, 2024 - Wiley Online Library
Doxorubicin‐based chemotherapy is a widely used first‐line treatment for breast cancer, yet
it is associated with various side effects, including splenic atrophy. However, the pathogenic …
it is associated with various side effects, including splenic atrophy. However, the pathogenic …
[HTML][HTML] Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective …
Q Li, Q Sun, Y Jian, J He, H Zhu, C Hong, L Zeng… - Discover Oncology, 2023 - Springer
Immune checkpoint inhibitors (ICIs) are safe and efficacious treatments for advanced
primary liver cancer (PLC). The efficacy of different ICIs in the treatment of liver cancer …
primary liver cancer (PLC). The efficacy of different ICIs in the treatment of liver cancer …